Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Galmed Pharmaceuticals Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

16 May 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - GALMED PHARMACEUTICALS LTD (GLMD-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 May 2015 Thomson Reuters Stock Report 10 $25.00

ValuEngine Industry Report for Medical-drugs(GLMD)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

28 May 2015 ValuEngine, Inc. 10 $49.00

US MARKET ANALYSIS AND FORECAST. 70 PAGE REPORT PUBLISH QUARTERLY. IN EACH REPORT YOU WILL FIND 12-MONTHS FORECASTS ANALYSIS TARGET PRICE VALUATION RATINGS AND CREUDE OIL DEPENDENCE FOR 7396 US STOCKS.

25 May 2015 Pechala's Reports 85 $1,000.00

GALMED PHARMACEUTICALS LTD (GLMD) - REPORT FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 May 2015 Pechala's Reports 1 $25.00

GALMED PHARMACEUTICALS LTD (GLMD) 12-months forecast

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 May 2015 Pechala's Reports 1 $15.00

ValuEngine Rating and Forecast Report for GLMD

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

18 May 2015 ValuEngine, Inc. 10 $25.00

Interview with the CFO: Galmed Pharmaceuticals Ltd. (GLMD)

23 Apr 2015 Wall Street Transcript ,The 4 $50.00

GLMD.OQ - Event Transcript of Galmed Pharmaceuticals Ltd conference call, Mar. 31, 2015 / 8:30AM ET

Edited Event Transcript of GLMD.OQ conference call, Mar. 31, 2015 / 8:30AM ET Boston, Mar 31, 2015 (Thomson StreetEvent...

31 Mar 2015 Thomson Reuters StreetEvents 8 $75.00

GALMED PHARMACEUTICALS- ARAMCHOL CLEARED TO START KEY NASH TRIAL

Galmed’s aramchol is expected to start a Phase IIb study in late 2014 for non-alcoholic steatohepatitis (NASH), an area that ...

18 Aug 2014 Edison Investment Research 2 $10.00